IOL Chemicals and Pharmaceuticals Ltd

Capital Structure and Liquidity IOL Chemicals and Pharmaceuticals has a debt-to-equity ratio of 0.07, indicating a conservative capital structure with minimal leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.89, suggesting it can cover short-term obligations but with limited excess liquidity. Free cash flow is negative at -639 million INR, driven by capital expenditures of -2,135.5 million INR, which may signal ongoing investment in operations. ### Profitability and Returns The company's return on equity (ROE) is 5.99%, and return on assets (ROA) is 4.24%, both below the typical thresholds for high-performing pharmaceutical firms. Gross profit of 6,652.6 million INR and operating income of 1,305.1 million INR indicate moderate profitability, but the net income of 1,010.7 million INR suggests some pressure from operating expenses. ### Segments and Geographic Exposure IOL Chemicals and Pharmaceuticals operates through two segments: Chemical and Pharmaceutical. The Chemical segment produces solvents and intermediates, while the Pharmaceutical segment focuses on active pharmaceutical ingredients (APIs). The company's revenue concentration is not disclosed, but the dual-segment model provides some diversification. ### Growth Trajectory The company's growth trajectory is not explicitly outlined in the provided data, but the negative free cash flow and significant capital expenditures suggest ongoing investment in operations. Analysts have assigned a mean price target of 110.00 INR, with a strong-buy recommendation from two analysts, indicating some optimism about future performance. ### Risk Factors The company faces a medium liquidity risk, with a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution potential in the near term. The risk assessment does not highlight any major regulatory or geopolitical risks, but the pharmaceutical industry is inherently subject to regulatory changes and patent expirations. ### Recent Events No specific recent events or filings are detailed in the provided data, but the company's financial snapshot and analyst estimates suggest a stable but not rapidly growing business. The strong-buy recommendation from analysts indicates some confidence in the company's future performance.